A fugitive who was discovered to have worked under an alias in the biotech industry has raised questions about how companies hired him despite his criminal history.[6179739] The FDA has also expressed concerns about a new treatment for Duchenne muscular dystrophy, citing issues with the company's study design and data analysis.[6153138][6023335]